Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From GC Pharma
Plus deals involving BioAtla/BeiGene, OliX/Thea, Chugai/Argenx, Shionogi/HanaVax, TaiGen/Luminairie, Novartis/1Yao.com, Sperogenix/Minoryx, Quantum/Orient EuroPharma and AtomWise/GC Pharma.
South Korean firm outlines R&D milestones for this year including progress with a plasma therapy for COVID-19, as well as other challenges and opportunities amid the pandemic.
The South Korean pharma firm, which has been focusing on North America, decides to sell two subsidiaries there as the prolonged coronavirus pandemic further delays commercial manufacturing of plasma products.
As a recent increase in silent virus spreaders in metropolitan areas raises concerns, South Korea unveils policy measures to support the development of COVID-19 drugs and vaccines, as well as to secure imports of such products if necessary.
- Contract Manufacturing Organization
- Other Names / Subsidiaries
- Ceragem Medisys
- Green Cross LabCell
- Green Cross Corporation